Lansoprazole prevents the progression of liver fibrosis in nonalcoholic steatohepatitis model rats
Abstract
Background: Lansoprazole increased the expression of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), which is a transcription factor, and their down-stream genes, including heme oxygenase 1 (HO-1) gene, which encodes an anti-oxidant protein in rat livers. Lansoprazole also indicated hepatoprotection in a drug-induced hepatitis animal model in our previous study. We examined whether the hepatoprotection inhibited the progression of nonalcoholic steatohepatitis (NASH) using NASH model rats.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.